Lipson Sheds Light on the Evolving Role of ctDNA in the Realm of Melanoma

Source: OncLive, December 2021

Evan J. Lipson, MD, discusses the role of ctDNA in the neoadjuvant, adjuvant, and metastatic settings in the realm of melanoma, remaining questions with this marker, and future directions to optimize its use in this disease.

The use of circulating tumor DNA (ctDNA) continues to evolve in the realm of melanoma, with opportunity for use as a potential blood-based marker in which positivity may be indicative of disease recurrence, according to Evan J. Lipson, MD, who added that it may also serve as a tool to clarify pseudoprogression or for long-term monitoring.

One study is focused on examining immunotherapy in patients with stage II melanoma who have ctDNA positivity after disease resection, according to Lipson. In many cases, patients can achieve cure through the surgical procedure alone. With this trial, investigators are seeking to utilize ctDNA positivity as a marker to determine who should receive adjuvant immunotherapy.

READ THE ORIGINAL FULL ARTICLE
Menu